gms | German Medical Science

16. Jahreskongress für Klinische Pharmakologie

Verbund Klinische Pharmakologie in Deutschland

09. - 10. Oktober 2014, Köln


Meeting Abstract (14vklipha01)

The impact of German benefit assessment on endpoint selection in clinical research and drug development in Germany – lessons (to be) learned

Patchev A, Rost M, Engler C, Obermeier M, Hautmann C
[Full Text]
Meeting Abstract (14vklipha02)

Induction of PCFT and OATP1A2 via vitamin D receptor activation in vitro is not confirmed in vivo in healthy volunteers after a 10-days treatment with 1,25-dihydroxyvitamin D3

Marti I, Claro da Silva T, Spanaus K, Gubler C, Kullak-Ublick GA, Jetter A
[Full Text]
Meeting Abstract (14vklipha03)

Therapeutic drug monitoring (TDM) of the HIV drugs abacavir, atazanavir, darunavir, efavirenz, emtricitabine, lamivudine, lopinavir, and nevirapine

Donnerer J
[Full Text]
Meeting Abstract (14vklipha04)

Serelaxin – from basic research to clinical practice in acute heart failure [invited speaker]

Dschietzig TB
[Full Text]
Meeting Abstract (14vklipha05)

Detection of medication errors requires more than just medication data

Plank-Kiegele B, Bürkle T, Müller F, Patapovas A, Sonst A, Pfistermeister B, Dormann H, Maas R
[Full Text]
Meeting Abstract (14vklipha06)

Dose individualisation of antiinfective drugs in clinical practice [invited speaker]

Frey OR, Röhr A, Helbig S, Köberer A
[Full Text]
Meeting Abstract (14vklipha07)

SATB1 as a putative therapeutic target in colorectal cancer

Frömberg A, Rabe M, Linnebacher M, Aigner A
[Full Text]
Meeting Abstract (14vklipha08)

Anabolic and other potentially performance enhancing agents in sports [invited speaker]

Thevis M
[Full Text]
Meeting Abstract (14vklipha09)

Around two thirds of the sildenafil used may be illegal Consumption of illicit sildenafil might dwarf the consumption of legitimate versions [invited speaker]

Venhuis BJ, de Voogt P, Emke E, Causanilles A, Keizers P
[Full Text]
Meeting Abstract (14vklipha10)

The effect of eye drops containing hyaluronic acid on tear film thickness in healthy subjects

Schmidl D, Kaya S, Schmetterer L, Witkowska K, Unterhuber A, Aranha Dos Santos V, Baar C, Garhöfer G, Werkmeister R
[Full Text]
Meeting Abstract (14vklipha11)

Clinical research in the doctor's practice: Possibilities and limitations. Strengths and weaknesses [invited speaker]

Hommer A
[Full Text]
Meeting Abstract (14vklipha12)

Finerenone (BAY 94-882): New Hope for Patients Suffering from Cardio/Renal Diseases [invited speaker]

Nowack C, Kolkhof P
[Full Text]
Meeting Abstract (14vklipha13)

Size matters? Clinical development outside large research sites – the industry perspective [invited speaker]

Baumgartner C
[Full Text]
Meeting Abstract (14vklipha14)

Comparison of pantoprazole concentrations in simultaneous cerebrospinal fluid and serum samples

Sigaroudi A, Stelzer C, Braun T, Schröter M, Kinzig M, Fuhr U, Holzgrabe U, Sörgel F
[Full Text]
Meeting Abstract (14vklipha15)

Specific challenges of topical drug therapy in ophthalmology [invited speaker]

Garhöfer G
[Full Text]
Meeting Abstract (14vklipha16)

Endurance sports and analgesics: a prospective cohort study on adverse event incidence and dose dependency

Renner B, Küster M, Oppel P, Niederweis U, Brune K
[Full Text]
Meeting Abstract (14vklipha17)

Old drugs: are they really safe and worth the (low) price? [invited speaker]

Brune K
[Full Text]
Meeting Abstract (14vklipha18)

Benefit assessment of older drugs [invited speaker]

Biester K
[Full Text]
Meeting Abstract (14vklipha19)

10 years as an inspector in small clinical research units: developments, retrospection, and perspective [invited speaker]

Hönel A
[Full Text]
Meeting Abstract (14vklipha20)

Plasma and soft tissue pharmacokinetics of ceftaroline after single and repeated administration of two dosing regimens of ceftaroline fosamil – a microdialysis study in healthy volunteers

Matzneller P, Lackner E, Severin P, Zeitlinger M
[Full Text]
Meeting Abstract (14vklipha21)

Quantitative significance of intestinal drug transporters for drug therapy [invited speaker]

Siegmund W
[Full Text]
Meeting Abstract (14vklipha22)

A survey among leading pharmaceutical companies on the impact of clinical trial registries for patient participation and recruitment

Yildirim O, Herdegen T, Michel MC
[Full Text]
Meeting Abstract (14vklipha23)

Silexan, an orally administered lavender oil preparation for anxiety disorders [invited speaker]

Dienel A
[Full Text]
Meeting Abstract (14vklipha24)

Novel Approaches for Dose Individualization in Anti-Cancer Drug Therapy [invited speaker]

Jaehde U
[Full Text]
Meeting Abstract (14vklipha25)

Assessment of the Inhibitory Potential of Spasmolytics on Major Human Cytochrome P450 Enzymes

Dahlinger D, Frechen S, Nücken D, Fuhr U
[Full Text]
Meeting Abstract (14vklipha26)

A Pharmacometric Model Characterizing the Time Course of the Adverse Events in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib

Suleiman AA, Frechen S, Scheffler M, Nogova L, Wolf J, Fuhr U
[Full Text]
Meeting Abstract (14vklipha27)

Up-to-date treatment options with tyrosine kinase inhibitors in advanced melanoma [invited speaker]

Eigentler T
[Full Text]
Meeting Abstract (14vklipha28)

Safety of Biologics [invited speaker]

Strangfeld A
[Full Text]
Meeting Abstract (14vklipha29)

Impact of frequently used pharmaceutical excipients on the function of human peptide and cation transporters

Otter M, Oswald S, Keiser M, Siegmund W
[Full Text]
Meeting Abstract (14vklipha30)

Absolute protein quantification of clinically relevant metabolizing enzymes by mass spectrometry-based targeted proteomics

Busch D, Gröer C, Drozdzik M, Siegmund W, Oswald S
[Full Text]
Meeting Abstract (14vklipha31)

Safety requirements and timing of safety studies throughout the clinical program for topical products [invited speaker]

Hughes-Formella B
[Full Text]
Meeting Abstract (14vklipha32)

Targeting metastatic colorectal cancer with the multikinase inhibitor regorafenib [invited speaker]

Strumberg D
[Full Text]
Meeting Abstract (14vklipha33)

Population pharmacokinetic model for cisplatin during intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC) in patients with platinum-sensitive recurrent epithelial ovarian cancer (EOC)

Fritsch A, Kullmann M, Zivanovic O, Abramian A, Hilger R, Kuhn W, Jaehde U
[Full Text]
Meeting Abstract (14vklipha34)

Treatment options for functional gastrointestinal diseases: Motility modulation beyond MCP and domperidone

Madisch A, Vinson BR, Kelber O, Nieber K, Storr M
[Full Text]
Meeting Abstract (14vklipha35)

Regulatory assessment of cardiovascular safety of medicinal products [invited speaker]

Mittmann C
[Full Text]
Meeting Abstract (14vklipha36)

Assessment of mucosal integrity of the upper gastrointestinal tract in healthy volunteers prior to treatment with drugs suspected to cause GI lesions

Scheidl E, Benz C, Loeff P, Groneck V, König A, Schulte-Fischedick A, Lück H, Fuhr U
[Full Text]
Meeting Abstract (14vklipha37)

Benefits and limitations of dosing recommendations from guidelines – How modelling can support evidence-based dose individualisation [invited speaker]

Schäftlein A
[Full Text]
Meeting Abstract (14vklipha38)

Klinische Studien an Nichteinwilligungsfähigen aus medizinrechtlicher Sicht [invited speaker]

Fischer G
[Full Text]
Meeting Abstract (14vklipha39)

Clinical studies on herbal medicines in children: A systematic literature analysis

Marquardt P, Kelber O, Kraft K, Nieber K
[Full Text]
Meeting Abstract (14vklipha40)

Herbal medicinal products in clinical guidelines: Horse chestnut seed extract as “well established use” medicinal product in chronic venous diseases

Müller J, Kelber O, Kraft K
[Full Text]
Meeting Abstract (14vklipha41)

Valerian: No Clinically Relevant Interactions

Kelber O, Kraft K, Nieber K
[Full Text]
Meeting Abstract (14vklipha42)

Clinical Trials – EU Regulation; 536/2014. View of the National Competent Authority (NCA) [invited speaker]

Stahl E
[Full Text]
Meeting Abstract (14vklipha43)

Anthracycline-induced cardiotoxicity: Molecular mechanisms and possible preventive strategies [invited speaker]

Henninger C, Fritz G
[Full Text]
Meeting Abstract (14vklipha44)

Galenic requirement for topical preparations from the clinical point of view [invited speaker]

Jünger M
[Full Text]
Meeting Abstract (14vklipha45)

New EU Regulation on “Clinical trials” – an industry perspective

Ruppert T
[Full Text]